Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
Belani, Chandra P, Nemunaitis, John J, Chachoua, Abraham, Eisenberg, Peter D, Raez, Luiz E, Cuevas, J Daniel, Mather, Cecile B, Benner, Rebecca J, Meech, Sandra J
Published in Cancer biology & therapy (01.07.2013)
Published in Cancer biology & therapy (01.07.2013)
Get full text
Journal Article
Abstract SS2-10: Impact of COVID-19 on study sites: Survey analysis from the noninterventional POLARIS study
Tripathy, Debu, Blum, Joanne L, Rocque, Gabrielle, Cuevas, J. Daniel, Specht, Jennifer, Corso, Steven, Francis, Jawad E, Mendez, Stephanie, Pope, Veneta, Cappelleri, Joseph, Wang, Yao
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma
Flinn, Ian W., Ervin, Thomas J., Boccia, Ralph V., Flora, Douglas B., Cuevas, J. Daniel, Thompson, Dana S., Shipley, Dianna L., Berdeja, Jesus G.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article